Latest news with #JAK
Fashion Network
4 hours ago
- Business
- Fashion Network
JAK adds Harvey Nichols to prestige UK stockists list
Footwear label JAK continues its UK expansion with an upcoming launch at high-end London department store Harvey Nichols. The minimalist Portuguese footwear brand will debut at the Knightsbridge department store on 20 September as part of its ongoing UK expansion. Having already built 'a loyal global following', this is the latest stage of the direct-to-consumer brand's journey into UK physical retail as it 'takes bold steps into one of the world's most influential fashion capitals'. It follows the brand's Selfridges and Browns debut earlier this year, 'marking another key step in [our] thoughtful rollout across the UK', it said. The curated selection at Harvey Nichols will include some of JAK's most important styles -- and will be in exclusive colourways for the UK market, it noted. 'With this new retail chapter, JAK continues to build its presence in key global cities while staying rooted in its original mission: to create high-quality, consciously made footwear that stands the test of time', it added. Isabel Henriques da Silva, co-founder of JAK in 2014 in Lisbon with José Maria Reffoios, added: 'Harvey Nichols…. shares our vision for timeless design and forward-thinking values [so] this partnership is an important step for JAK in our UK journey.'
Globe and Mail
4 hours ago
- Business
- Globe and Mail
JAK Inhibitors Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, ' Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the JAK Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the JAK Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the JAK Inhibitors Treatment Landscape. Click here to read more @ JAK Inhibitors Pipeline Outlook Key Takeaways from the JAK Inhibitors Pipeline Report In June 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care. DelveInsight's JAK Inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for JAK Inhibitors treatment. The leading JAK Inhibitors Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Promising JAK Inhibitors Pipeline Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. Stay informed about the cutting-edge advancements in JAK Inhibitors Treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ JAK Inhibitors Clinical Trials Assessment JAK Inhibitors Emerging Drugs Profile Povorcitinib: Incyte Corporation Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo. CPL409116: Celon Pharma CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease. ATI-2138: Aclaris Therapeutics ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities. SDC 1802: Sareum SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer. The JAK Inhibitors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of JAK Inhibitors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for JAK Inhibitors Treatment. JAK Inhibitors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. JAK Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the JAK Inhibitors market. Get a detailed analysis of the latest innovations in the JAK Inhibitors pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitors Unmet Needs JAK Inhibitors Companies Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical JAK Inhibitors Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in JAK Inhibitors Treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ JAK Inhibitors Market Drivers and Barriers, and Future Perspectives Scope of the JAK Inhibitors Pipeline Report Coverage- Global JAK Inhibitors Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma and others. JAK Inhibitors Pipeline Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, GSK3196165 (Otilimab), Sarilumab, Ruxolitinib 0.15% Cream QD and others. JAK Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination JAK Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of JAK Inhibitors Pipeline on our website @ JAK Inhibitors Emerging Drugs and Companies Table of Contents Introduction Executive Summary Janus Kinase (JAK) Inhibitor: Overview Pipeline Therapeutics Therapeutic Assessment Janus Kinase (JAK) Inhibitor– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Povorcitinib: Incyte Corporation Drug profiles in the detailed report….. Mid Stage Products (Phase II) CPL409116: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) ATI-2138: Aclaris Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SDC 1802: Sareum Drug profiles in the detailed report….. Inactive Products Janus Kinase (JAK) Inhibitor Key Companies Janus Kinase (JAK) Inhibitor Key Products Janus Kinase (JAK) Inhibitor- Unmet Needs Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion Janus Kinase (JAK) Inhibitor Analyst Views Janus Kinase (JAK) Inhibitor Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Medscape
16-07-2025
- Health
- Medscape
Infections Common in IBD, Rates Vary by Treatment
TOPLINE: Patients with inflammatory bowel disease (IBD) experienced higher rates of mild and moderate infections. Women, smokers, those with multiple comorbidities, and those with exposure to certain IBD medications showed significantly higher rates of infections. METHODOLOGY: Researchers conducted a prospective observational study (June 2020 to July 2021) to evaluate the incidence of and risk factors for mild, moderate, and severe infections in 629 patients (mean age, 48.3 years; 58.2% women) with IBD who used an established remote monitoring platform for IBD management. They used the Patient-Reported Infections Questionnaire, a validated seven-item tool with a 3-month recall period, to collect data on 15 infection categories, including respiratory tract, urinary tract, and skin conditions and COVID-19. The presence or absence of disease activity was confirmed using a combination of monitoring questionnaire scores for patient-reported disease activity and faecal calprotectin levels. The severity of infection was categorised on the basis of the type and route of treatment as mild (self-limiting or requiring topical treatment), moderate (requiring oral treatment), or severe (requiring hospitalisation and/or intravenous treatment). Exposure to different medications, alone or in combination, was also assessed. TAKEAWAY: Overall, 991 infections were reported during 573.8 person-years of follow-up, with an overall incidence rate (IR) of 172.7 per 100 person-years, predominantly comprising mild (68%; IR, 117.5 per 100 person-years) and moderate (29.5%; IR, 50.9 per 100 person-years) infections. Women demonstrated significantly higher rates of infections than men (IR ratio [IRR], 1.70; P < .001), with increased rates of infections among current smokers vs non-smokers (IRR, 1.43; P = .004). Patients with a Charlson Comorbidity Index score > 2 had significantly higher rates of infections than those with lower scores (IRR for all infections, 1.69; P = .031). Glucocorticoid use more than doubled the rates of infections (IRR, 2.02; P = .033), and compared with no treatment, the use of JAK inhibitors, immunomodulator monotherapy, anti-TNF monotherapy, and combination therapy with anti-TNF and immunomodulators were associated with increased rates of infections. IN PRACTICE: "Clinicians should adopt a holistic approach that includes vigilant monitoring, preferably using validated tools, such as the PRIQ [Patient-Reported Infections Questionnaire], to identify patients with frequent mild or moderate infections. In addition, proactive application of preventive strategies, like vaccination, optimizing nutritional status, counselling for lifestyle modifications, and careful selection of therapies, should be used to reduce infection risk," the authors of the study wrote. SOURCE: This study was led by Ashkan Rezazadeh Ardabili, MD, Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. It was published online on July 09, 2025, in the Journal of Crohn's and Colitis. LIMITATIONS: The study's 1‐year follow‐up coincided with COVID‐19 public health measures, likely underestimating overall rates of infections. This study was underpowered to precisely assess rare outcomes, and its real‐world design limited the control over the distribution of medication groups, especially when stratifying the analysis by IBD subtype. DISCLOSURES: This study was supported in part by an investigator-initiated research grant from Takeda. Some authors reported receiving grants, non-financial support, and research prizes and serving as speaker, advisor, and/or principal investigator for various institutions and pharmaceutical companies, including Takeda. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
11-07-2025
- Health
- Medscape
Good News for Tofacitinib in Recent Study of Acute Severe UC
A head-to-head comparison of the JAK inhibitor drug tofacitinib and chimeric monoclonal antibody infliximab in the treatment of acute severe ulcerative colitis (ASUC) shows that, contrary to concerns, tofacitinib is not associated with worse postoperative complications and in fact may reduce the risk of the need for colectomy. 'Tofacitinib has shown efficacy in managing ASUC, but concerns about postoperative complications have limited its adoption,' reported the authors in research published in Clinical Gastroenterology and Hepatology. 'This study shows that tofacitinib is safe and doesn't impair wound healing or lead to more infections if the patient needs an urgent colectomy, which is unfortunately common in this population,' senior author Jeffrey A. Berinstein, MD, of the Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan, told Medscape Medical News. Recent treatment advances for UC have provided significant benefits in reducing the severity of symptoms; however, about a quarter of patients go on to experience flares, with fecal urgency, rectal bleeding, and severe abdominal pain of ASUC potentially requiring hospitalization. The standard of care for those patients is rapid induction with intravenous (IV) corticosteroids; however, up to 30% of patients don't respond to those interventions, and even with subsequent treatment of cyclosporine and infliximab helping to reduce the risk for an urgent colectomy, patients often don't respond, and ultimately, up to a third of patients with ASUC end up having to receive a colectomy. While JAK inhibitor therapies, including tofacitinib and upadacitinib, have recently emerged as potentially important treatment options in such cases, showing reductions in the risk for colectomy, concerns about the drugs' downstream biologic effects have given many clinicians reservations about their use. 'Anecdotally, gastroenterologists and surgeons have expressed concern about JAK inhibitors leading to poor wound healing, as well as increasing both intraoperative and postoperative complications, despite limited data to support these claims,' the authors wrote. To better understand those possible risks, first author Charlotte Larson, MD, of the Department of Internal Medicine, Michigan Medicine, and colleagues conducted a multicenter, retrospective, case-control study of 109 patients hospitalized with ASUC at two centers in the US and 14 in France. Of the patients, 41 were treated with tofacitinib and 68 with infliximab prior to colectomy. Among patients treated with tofacitinib, five (12.2%) received infliximab and four (9.8%) received cyclosporine rescue immediately prior to receiving tofacitinib during the index admission. In the infliximab group, one (1.5%) received rescue cyclosporine. In a univariate analysis, the tofacitinib-treated patients showed significantly lower overall rates of postoperative complications than infliximab-treated patients (31.7% vs 64.7%; odds ratio [OR], 0.33; P = .006). The tofacitinib-treated group also had lower rates of serious postoperative complications (12% vs 28.9; OR, 0.20; P = .016). After adjusting for multivariate factors including age, inflammatory burden, nutrition status, 90-day cumulative corticosteroid exposure and open surgery, there was a trend favoring tofacitinib but no statistically significant difference between the two treatments in terms of serious postoperative complications ( P = .061). However, a significantly lower rate of overall postoperative complications with tofacitinib was observed after the adjustment (odds ratio, 0.38; P = .023). Importantly, a subanalysis showed that the 63.4% of tofacitinib-treated patients receiving the standard FDA-approved induction dose of 10 mg twice daily did indeed have significantly lower rates than infliximab-treated patients in terms of serious postoperative complications (OR, .10; P = .031), as well as overall postoperative complications (OR, 0.23; P = .003), whereas neither of the outcomes were significantly improved among the 36.6% of patients who received the higher-intensity thrice-daily tofacitinib dose ( P = .3 and P = .4, respectively). Further complicating the matter, in a previous case-control study that the research team conducted, it was the off-label, 10 mg thrice-daily dose of tofacitinib that performed favorably and was associated with a significantly lower risk for colectomy than the twice-daily dose (hazard ratio 0.28; P = .018); the twice-daily dose was not protective. Berinstein added that a hypothesis for the benefits overall, with either dose, is that tofacitinib's anti-inflammatory properties are key. 'We believe that lowering inflammation as much as possible, with the colon less inflamed, could be providing the benefit in lowering complications rate in surgery,' he explained. Regarding the dosing, 'it's a careful trade-off,' Berinstein added. 'Obviously, we want to avoid the need for a colectomy in the first place, as it is a life-changing surgery, but we don't want to increase the risk of infections.' In other findings, the tofacitinib group had no increased risk for postoperative venous thrombotic embolisms (VTEs), which is important as tofacitinib exposure has previously been associated with an increased risk for VTEs independent of other prothrombotic factors common to patients with ASUC, including decreased ambulation, active inflammation, corticosteroid use, and major colorectal surgery. 'This observed absence of an increased VTE risk may alleviate some of the hypothetical postoperative safety concern attributed to JAK inhibitor therapy in this high-risk population,' the authors wrote. Overall, the results underscore that 'providers should feel comfortable using this medication if they need it and if they think it's most likely to help their patients avoid colectomy,' Berinstein said. 'They should not give pause over concerns of postoperative complications because we didn't show that,' he said. Commenting on the study, Joseph D. Feuerstein, MD, of the Department of Medicine and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, noted that, in general, in patients with ASUC who fail on IV steroids, 'the main treatments are infliximab, cyclosporine, or a JAK inhibitor like tofacitinib or upadacitinib, [and] knowing that if someone needs surgery, the complication rates are similar and that pre-operative use is okay is reassuring.' Regarding the protective effect observed with some circumstances, 'I don't put too much weight into that,' he noted. '[One] could speculate that it is somehow related to faster half-life of the drug, and it might not sit around as long,' he said. Feuerstein added that 'the study design being retrospective is a limitation, but this is the best data we have to date.'
Time of India
07-07-2025
- Health
- Time of India
26 years on, war hero revisits Point 5140, relives Kargil memories
1 2 Lucknow: Twenty-six years after the Kargil War , Colonel Rajesh W Adhau, Sena Medal, retraced his steps to Point 5140, a towering peak at 16,800 feet in the rugged Kargil terrain. On July 7, 2025, he stood atop the same ground — famously known as Tiger Hill — where his comrade, Captain Vikram Batra, (Param Vir Chakra-posthumous), sacrificed his life on July 7, 1999, while capturing the strategic peak from enemy forces. The climb, undertaken with the current commanding officer of 13 Jammu and Kashmir Rifles (JAK), Colonel Rajesh Bandhe, and a dozen soldiers, was an emotional one for Adhau. As the Regimental Medical Officer (RMO) of 13 JAK during the 1999 War, Adhau, with just one year of service, faced relentless challenges. Tasked with keeping wounded soldiers alive under heavy shelling, he administered first aid to 97 14 soldiers died in his care, nine from fatal last conversation with Batra, on the evening of July 6, 1999, was a poignant memory — Batra had requested medicine for a headache, unaware of the fate awaiting him the next morning. Reflecting on the trek, Adhau shared, "It was an emotional moment. We fought against all odds to reclaim this land." Upon reaching Point 5140, he called Vishal Batra, Vikram's brother, to share the significance of the moment. Currently, Adhau serves as the head of a Level 3 hospital in Congo under a UN peacekeeping mission. TNN
